SOLCF
SOL GLOBAL INVTS CORP
stockOTC
scythian is a pharmaceutical development company currently undertaking pre-clinical testing at the university of miami on a combination drug therapy for the treatment of traumatic brain injury ("tbi") and concussion. tbi happens when there is a major impact to the head or subjected to accelerative forces. it frequently results in both initial damage from the impact itself and significant subsequent damage from inflammation and the body's own immune response. a significant amount of brain injury occurs from the inflammatory and immune response. scythian's pharmaceutical approach aims to reduce both the inflammation and the immune response by using a combination of two drugs as the acute emergency room or post injury treatment. a broad based u.s. provisional patent application has been filed utilizing drug combinations which affect the endocannabinoid pathway to treat concussions. scythian's second business line is its application to become a licensed producer of medical marijuana in can
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.03 | 2026-09-28 | +158.96% | -77.336 |
| 1M | 0.07 | 2026-09-03 | -3.85% | 39.458 |
| 3M | 0.04 | 2026-07-07 | +62.50% | -72.878 |
| 6M | 0.03 | 2026-04-06 | +101.55% | -30.701 |
| 1Y | 0.04 | 2025-10-03 | +69.89% | -5.479 |
| 2Y | 0.03 | 2024-10-04 | +94.61% | — |
| 5Y | 2.81 | 2021-10-04 | -97.69% | -0.748 |
SOL GLOBAL INVTS CORP (OTC:SOLCF) stock price today is $0.07, and today's volume is 501. SOLCF is up 0.000% today. The 30 day average volume is 3,536. SOLCF market cap is $3.54M with 54.44M shares outstanding.